Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863707 · ClinicalTrials.gov registry record · Phase 4
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 511
- Enrollment target
NCT00863707: Completed Phase 4 study, sponsored by Astellas Pharma.
NCT00863707 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 511 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00863707, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 511 participants
- Enrollment target
Study Summary
This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
Primary Outcome
The data represents the numbers of subjects reporting Serious TEAEs. TEAEs were defined as Adverse Events (AEs) starting or worsening after administration of the test drug.
Interventions
- DRUG Placebo
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00863707 record still lists
NCT00863707 is an interventional study that assigns participants to a tested intervention. The registered 511 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00863707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00863707 about?
NCT00863707 is a clinical study titled "A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment". This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
What is the current status of trial NCT00863707?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 511 participants. The study started on 2009-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00863707?
The interventions under investigation include: Placebo (DRUG), Regadenoson (DRUG).
Who is sponsoring clinical trial NCT00863707?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00863707's enrollment target sits among peer trials
511 162nd of 2000 higher than 1,839 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia